Table 2: Comparison of clinicopathological characteristics between patients who had developed hepatocellular carcinoma (HCC) and those who had not developed HCC at follow-up.

OverallFemale
Patients who had developed HCC at follow-upPatients who had not developed HCC at follow-up Patients who had developed HCC at follow-upPatients who had not developed HCC at follow-up

Number of patients1316611144
Number of male patients2220.687NANANA
Age of Dx of PBC (years)*63 (46–77)56 (22–85)0.07263 (46–77)56 (24–85)0.049
PBC Stage at Dx of PBC (I/II/III/IV)2/4/3/499/38/16/130.0042/3/3/386/34/14/100.011
Number of symptomatic patients8450.0227420.037
 Pruritus4330.4744320.282
 Jaundice180.501160.409
 Ascites031031
 Varices5120.0034110.013
Biochemical data
 AST (IU/L)*78 (30–231)46 (16–258)0.08877 (30–231)46 (16–258)0.15
 ALT (IU/L)*51 (22–319)45 (10–329)0.64447.5 (22–319)41 (10–329)0.761
 ALP (IU/L)*402.5 (175–1185)543.5 (94–2985)0.314402.5 (175–1185)543.5 (112–2985)0.489
GTP (IU/L)*174.5 (16–470)173.5 (13–1349)0.285114 (16–470)173.5 (13–1004)0.181
 lgG (mg/dL)*2165 (1030–4532)1655 (778–3900)0.0212165 (1030–4532)1660 (778–3900)0.049
 lgM (mg/dL)*405 (136–918)351.5 (48–1660)0.364359.5 (136–918)336 (48–1660)0.352
 Alb (g/dL)*3.7 (1.9–4.6)4.2 (2.0–5.1)0.0164.0 (1.9–4.6)4.2 (2.0–5.0)0.085
 T-Bil (mg/dL)*0.7 (0.3–2.5)0.7 (0.1–6.3)0.9250.7 (0.3–2.5)0.7 (0.1–6.3)0.888
 Plt (×104/ L)*12.4 (5.3–24.4)21.4 (5.3–58.1)0.00112.3 (5.3–21.8)21.0 (5.3–48.6)0.001
 PT (%)*96.5 (57.0–117.0)100.9 (44.0–139.0)0.20493.0 (57.0–117.0)100.9 (44.0–139.0)0.123
ANA positive71060.6586980.579
Brinkman index*0 (0–400)0 (0–1575)0.1750 (0-0)0 (0–940)0.12
Number of patients with a history of blood transfusion3200.4153170.285
Number of patients with a history of drinking0111071
Number of patients with a familial history of malignancy3610.3592560.261
Number of patients with a familial history of liver disease1250.7640240.337
Number of patients with DM2170.6322140.317
Number of patients with HT5270.0594220.09
Number of patients with HL34013340.725
Number of patients with autoimmune disease5530.7595510.528
 Sjogren’s syndrome22412241
 Hashimoto's disease3150.1283150.12
 Rheumatoid arthritis11511141
 Scleroderma0150.6060150.602
 Systemic lupus erythematosus021011
BMI*24.3 (13.8–27.4)22.6 (14.3–33.1)0.34124.3 (15.8–27.4)22.6 (16.0–32.5)0.536
Number of patients with medications
 UDCA/BF/UDCA + BF/none13/0/0/0131/1/29/50.38811/0/0/0116/1/22/50.512
Number of patients with biochemical response to UDCA and of those with medications
 Responder/non-responder/BF only/no
 medication (Rotterdam)
11/2/0/0141/19/1/50.9119/2/0/0123/15/1/50.696
 Responder/non-responder/BF only/no
 medication (Barcelona)
9/4/0/080/80/1/50.7017/4/0/067/71/1/50.816
 Responder/non-responder/BF only/no
 medication (Paris)
12/1/0/0134/26/1/50.83210/1/0/0119/19/1/50.905
 Responder/non-responder/BF only/no
 medication (Toronto)
11/2/0/0130/30/1/50.9149/2/0/0113/25/1/50.928
Modalities (US/CT/MRI/US-CT/US-MRI/CT-MRI/US-CT-MRI)12/0/0/1/0/0/0129/10/0/22/3/1/10.9610/0/0/1/0/0/0114/7/0/18/3/1/10.985
HCC screening interval (months)9 (6–12)6 (6–12)0.43512 (6–12)6 (6–12)0.413

*Data expressed as median (range); Alb: albumin; ALP: alkaline phosphatase; AMA: anti-mitochondrial antibody; ANA: antinuclear antibody; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BF: bezafibrate; BMI: body mass index; CT: computer tomography; DM: diabetes mellitus; Dx: diagnosis; -GTP: -glutamyltranspeptidase; HCC: hepatocellular carcinoma; HT: hypertension; HL: hyperlipidemia; MRI: magnetic resonance imaging; NA: not applcable; PBC: primary biliary cirrhosis; Plt: platelet; PT: prothrombin time; T-Bil: total bilirubin; UDCA: ursodeoxycholic acid; US: ultrasonography. Responses were defined as biochemical response to UDCA according to the Barcelona, Paris, Rotterdam, and Toronto definitions. These modalities were alternately applied to the patients.